Revenue Growth: 151%
Profit Growth: 65%
Total Return: 105%
SXC is both a pharmacy benefits manager (PBM) and a service provider to PBMs. With some $72 billion in branded drugs losing patent protection in the next five years, sales of generic
alternatives are likely to rise. SXC's PBM unit, which acts as middleman between the insurance company and the pharmacy, could be the beneficiary: It makes more money each time a person
uses a generic drug rather than a branded drug. Health care reform also means more people will be covered by Medicaid, which could benefit both of SXC's business lines.
SXC also stands to gain from growth in the use of specialty drugs like those for rheumatoid arthritis. SXC expanded its contract with one of its clients, HealthSpring, which focuses on
specialty drugs, and acquired MedFusionRx, a specialty pharmacy provider, in December.
Get stock quote: SXCI
Revenue ($ millions):
$2593.9Net Income ($ millions):
$68.2Industry: Health Care
L. Michael Cacace, Douglas G. Elam, Betsy Feldman, Kathleen Smyth, and Anne Vandermey, with Josh Dawsey, Mina Kimes, and Sam Silverman